Slow dose escalation matters more than the specific medication
LAS VEGAS Adjunctive use of GLP-1 receptor agonists may reduce steroid dependence and lead to fewer hospitalizations among patients with Crohns disease and overweight or obesity, according to data presented at Crohns & Colitis Congress
IN THIS EPISODE - What a peptide actually is, and why your GLP-1 is NOT the same thing as BPC-157 or TB-500 - The seven peptides the FDA is reviewing: BPC-157, KPV, TB-500 (the "Wolverine complex"), MOTS-c, DSIP, Semax, and Epitalon - The "funding gap" why peptides that can't be patented never get human clinical trials - Six things the FDA worries about in an unlabeled vial, from identity and purity to the cancer/angiogenesis risk - The two questions that tell you if a peptide provider is legitimate (503A/B pharmacies and third-party certificates of analysis) ABOUT THE GUEST Tanna Donalson is a Physician Assistant and Owner of Redbud Medical in Denver Colorado
doi: 10.2991/jegh.k.191028.001 2 BommerCSagalovaVHeesemannEManne-GoehlerJAtunRBrnighausenTet al
Whether you use medication, focus on lifestyle changes, or try both, the most important thing is to find a plan you can stick with for better health
